Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Nature Communications

Volumn 7, Issue , 2016, Pages

  Koyama, Shohei ^a,b   Akbay, Esra A ^a,b   Li, Yvonne Y ^a,b   Herter Sprie, Grit S ^a,b   Buczkowski, Kevin A ^a   Richards, William G ^b   Gandhi, Leena ^a   Redig, Amanda J ^a   Rodig, Scott J ^b   Asahina, Hajime ^a,b   Jones, Robert E ^a   Kulkarni, Meghana M ^a   Kuraguchi, Mari ^a   Palakurthi, Sangeetha ^a   Fecci, Peter E ^c   Johnson, Bruce E ^a,b   Janne, Pasi A ^a,b   Engelman, Jeffrey A ^d   Gangadharan, Sidharta P ^e   Costa, Daniel B ^e   Freeman, Gordon J ^a,b   Bueno, Raphael ^b   Hodi, F Stephen ^a,b   Dranoff, Glenn ^a,b   Wong, Kwok Kin ^a,b   Hammerman, Peter S ^a,b,f   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CARBOPLATIN; ERLOTINIB; PACLITAXEL; PEMETREXED; PROGRAMMED DEATH 1 ANTIBODY; T CELL IMMUNOGLOBULIN MUCIN 3 BLOCKING ANTIBODY; UNCLASSIFIED DRUG; CD274 PROTEIN, MOUSE; HAVCR2 PROTEIN, MOUSE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; VIRUS RECEPTOR;

ANTIBODY; APOPTOSIS; CELLS AND CELL COMPONENTS; GENE EXPRESSION; IMMUNE SYSTEM; INHIBITION; LIGAND; RODENT; SURVIVAL; TUMOR;

ADAPTIVE RESISTANCE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HUMAN; IMMUNITY; LUNG ADENOCARCINOMA; MALE; MIDDLE AGED; MOUSE; NONHUMAN; RAT; THERAPY RESISTANCE; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; ADAPTIVE IMMUNITY; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS;

ADAPTIVE IMMUNITY; AGED; ANIMALS; ANTIGENS, CD274; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, VIRUS;

EID: 84958555198     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10501     Document Type: Article

References (37)

1. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
2. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
3. Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., Wolchok, J. D. Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185-202 (2014).
4. Keir, M. E., Butte, M. J., Freeman, G. J., Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
5. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
6. Gros, A. et al. PD-1 identifies the patient-specific CD8(\+) tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246-2259 (2014).
7. Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064-5074 (2014).
8. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
9. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
10. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014).
11. Cardarella, S., Johnson, B. E. The impact of genomic changes on treatment of lung cancer. Am. J. Respir. Crit. Care. Med. 188, 770-775 (2013).
12. Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
13. Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123-135 (2015).
14. Rizvi, N. A. et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16, 257-265 (2015).
15. Ohashi, K., Maruvka, Y. E., Michor, F., Pao, W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J. Clin. Oncol. 31, 1070-1080 (2013).
16. Awad, M. M. et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 368, 2395-2401 (2013).
17. Akbay, E. A. et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3, 1355-1363 (2013).
18. Gao, S. P. et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117, 3846-3856 (2007).
19. Ancrile, B., Lim, K. H., Counter, C. M. Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 21, 1714-1719 (2007).
20. Zhu, C. et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245-1252 (2005).
21. Vega-Carrascal, I. et al. Dysregulation of TIM-3-galectin-9 pathway in the cystic fibrosis airways. J. Immunol. 186, 2897-2909 (2011).
22. Huang, Y. H. et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 517, 386-390 (2015).
23. DeKruyff, R. H. et al. T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells. J. Immunol. 184, 1918-1930 (2010).
24. Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187-2194 (2010).
25. Sakuishi, K. et al. TIM3FOXP3 regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2, e23849 (2013).
26. Jin, H. T. et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl Acad. Sci. USA 107, 14733-14738 (2010).
27. Sakuishi, K., Jayaraman, P., Behar, S. M., Anderson, A. C., Kuchroo, V. K. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol. 32, 345-349 (2011).
28. Verbrugge, I. et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res. 72, 3163-3174 (2012).
29. Anderson, A. C. Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol. Res. 2, 393-398 (2014).
30. Zhou, Q. et al. Coexpression of Tim-3 and PD-1 identifies a CD8\+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117, 4501-4510 (2011).
31. Ngiow, S. F. et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71, 3540-3551 (2011).
32. Gettinger, S., Herbst, R. S. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer J. 20, 281-289 (2014).
33. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577-581 (2014).
34. Li, D. et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12, 81-93 (2007).
35. Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356 (2008).
36. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511-515 (2010).
37. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).